Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|October 6, 2016
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemiaJuan Eduardo Megías-Vericat, Pau Montesinos, María José Herrero, et al.
Journal of Clinical Apheresis|May 8, 2021
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in SpainBlanca Boluda, Antonio Solana-Altabella, Isabel Cano, et al.
European Journal of Haematology|February 20, 2021
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from SpainAntonio Solana-Altabella, Blanca Boluda, Rebeca Rodríguez-Veiga, et al.
Annals of Hematology|April 29, 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patientsMaría P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, et al.
Heliyon|February 7, 2024
Silica-coated magnetic particles for efficient RNA extraction for SARS-CoV-2 detectionNatalia Capriotti, Leslie C Amorós Morales, Elisa de Sousa, et al.
Leukemia & Lymphoma|June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patientsBlanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
European Journal of Clinical Pharmacology|August 30, 2025
Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemiaAntonio Solana-Altabella, Carles Iniesta-Navalón, Maria Chovi-Trull, et al.
Cancers|May 16, 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid LeukemiaBlanca Boluda, Antonio Solana-Altabella, Isabel Cano, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Differences in <i>ex-vivo</i> Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaJuan Eduardo Megías-Vericat, David Martínez-Cuadrón, Joaquín Martínez López, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Pageof 17